Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what meetings representatives from NICE (a) have had and (b) plan to have with Pfizer during the consultation period for palbociclib (Ibrance) since the publication of the draft guidance on that drug on 3 February 2017.

The National Institute for Health and Care Excellence has advised that a meeting with Pfizer to discuss the appraisal of palbociclib took place on 22 February 2017.